LONDON, Jan 24 (Reuters) - GlaxoSmithKline said onFriday European regulators had given the green light to itsonce-weekly diabetes drug albiglutide, which it is marketing asEperzan.
Albiglutide belongs to the same class of injectable GLP-1drugs as Victoza, from Novo Nordisk, and Byetta andBydureon, from Bristol-Myers Squibb and AstraZeneca.
A positive recommendation for a drug by the EuropeanMedicines Agency is generally followed by a marketingauthorisation by the European Commission. GSK said a finaldecision was anticipated later this quarter.
Last year regulators in the United States pushed back anapproval decision on the drug until April 15.